235980.KQ
MedPacto, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 2,795.00
−0.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.0B | 3.9B | — | — | — |
| Cost of Revenue | 5.4B | 4.7B | 1.5B | 1.8B | 1.9B |
| Gross Profit | (385.5M) | (770.7M) | (1.5B) | (1.8B) | (1.9B) |
| Operating Expenses | |||||
| R&D Expense | 11.0B | 9.2B | 16.7B | 24.2B | 31.9B |
| SG&A Expense | 1.8B | 1.1B | 3.6B | 4.4B | 5.1B |
| General & Admin Expense | 171.5M | 197.9M | 8.0M | 264.7M | 250.6M |
| Selling & Marketing Expense | 995.0M | 925.2M | 1.0B | 1.4B | 1.0B |
| Other Expenses | 2.3B | 3.0B | 2.6B | 710.00 | (1.6B) |
| Total Operating Expenses | 15.0B | 13.3B | 20.3B | 28.6B | 35.4B |
| Cost and Expenses | 20.4B | 17.9B | 21.8B | 28.8B | 37.2B |
| Operating Income (EBIT) | (15.4B) | (14.0B) | (21.8B) | (28.8B) | (37.2B) |
| Non-Operating | |||||
| Interest Income | 885.4M | 1.2B | 1.7B | 388.5M | 1.3B |
| Interest Expense | 127.1M | 117.3M | 91.9M | 493.2M | 9.6B |
| Net Interest Income | 758.3M | 1.1B | 1.6B | (104.8M) | (8.3B) |
| Other Non-Op Income/Expense | 1.3B | 1.2B | 2.1B | (6.2B) | 1.5B |
| Non-Operating Income (excl Interest) | (546.3M) | — | (2.2B) | 5.7B | (11.6B) |
| EBT (Pre-Tax Income) | (14.1B) | (12.8B) | (19.7B) | (34.9B) | (35.8B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (14.1B) | (12.8B) | (20.1B) | (35.3B) | (35.8B) |
| Earnings from Cont. Ops | (14.1B) | (12.8B) | (19.7B) | (34.9B) | (35.2B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.1B) | (12.8B) | (20.1B) | (35.3B) | (35.8B) |
| Per Share | |||||
| Basic EPS | (₩413) | (₩374) | (₩598) | (₩1,665) | (₩1,456) |
| Diluted EPS | (₩413) | (₩374) | (₩598) | (₩1,665) | (₩1,456) |
| Revenue Per Share | ₩146 | ₩114 | ₩0 | ₩0 | ₩0 |
| Shares | |||||
| Basic Shares Outstanding | 34.3M | 34.2M | 33.7M | 21.2M | 24.6M |
| Diluted Shares Outstanding | 34.3M | 34.2M | 33.7M | 21.2M | 24.6M |
| Profitability Metrics | |||||
| EBITDA | (14.1B) | (12.9B) | (18.1B) | (32.6B) | (23.7B) |
| D&A | 1.1B | 1.2B | 1.5B | 1.8B | 1.9B |
| EBIT | (15.2B) | (14.0B) | (19.6B) | (34.4B) | (25.6B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026